F5 Inc vs Nuwellis Inc — how do they compare? F5 Inc trades at $460.99 (market cap $26.42B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: F5 Inc is far larger — about 12009.1× Nuwellis Inc's market cap, and F5 Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Nuwellis Inc for 26 Days on average.
| FFIV | NUWE | |
|---|---|---|
Market Cap | $26.42B | $2.20M |
Volume | 454,868 | 121,544 |
Sector | Technology | Health |
52-Week High | $469.79 | $146.65 |
52-Week Low | $223.99 | $0.68 |
Typical Hold Time | 38 Days | 26 Days |
Enterprise Value | $25.06B | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $466.65, down 0.67% on the day, as the stock consolidates near recent highs following strong year-to-date performance. The company continues to demonstrate robust fundamentals with revenue growth accelerating to $3.09 billion in 2025 and net income reaching $692 million, representing a 22.4% margin. Recent analyst recognition as a leader in WAAP platforms and AI security positions F5 well in the growing cybersecurity market. Technical indicators show the stock trading near resistance at $468 with bullish moving averages but overbought RSI readings suggesting potential near-term consolidation.
F5 presents a compelling growth story with consistent earnings beats and expanding profitability, though current valuation multiples appear elevated. The main investment opportunity lies in the company's leadership in application security and AI-driven solutions, while risks include competitive pressures and execution challenges in maintaining growth momentum. Analyst consensus remains cautiously optimistic with a $416.60 price target, indicating potential downside from current levels despite the positive business trajectory.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →